Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07397611 · ClinicalTrials.gov registry record · Phase 2

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

A Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
Phase 2
Development phase
32
Enrollment target
3
Study locations

NCT07397611 is a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 32 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07397611, a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC). The names of the study drugs involved in this study are: * Casdatifan (a type of HIF-2α inhibitor) * Zimberelimab (a type of monoclonal antibody)

Conditions Studied

Renal Cell Carcinoma Kidney Cancer Kidney Neoplasm Renal Carcinoma

Interventions

  • DRUG Zimberelimab
  • DRUG Casdatifan

Study Locations (3)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2026-03-09
Est. Completion 2029-09-30
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07397611

The ClinicalTrials.gov registry entry for NCT07397611 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (87% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.

NCT07397611 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07397611 about?

NCT07397611 is a clinical study titled "Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC". The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC). The names of the study drugs involved in this study are: * Casdatifan (a type...

What is the current status of trial NCT07397611?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2026-03-09. Estimated completion is 2029-09-30.

What conditions does trial NCT07397611 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma.

What interventions are being tested in trial NCT07397611?

The interventions under investigation include: Zimberelimab (DRUG), Casdatifan (DRUG).

Who is sponsoring clinical trial NCT07397611?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07397611 being conducted?

This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Kidney Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.